R A Ferrand1, G H Bothamley, A Whelan, H M Dockrell. 1. Immunology Unit, Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom. rabferr@fastmail.fm
Abstract
OBJECTIVE: To investigate T-cell responses to ESAT-6 by an interferon-gamma (IFN-gamma) ex vivo enzyme-linked immunospot (ELISpot) assay in tuberculosis (TB) patients early during treatment and in patients who have completed a course of anti-tuberculosis chemotherapy. DESIGN: T-cell responses following overnight stimulation with 6-kD early secretory antigenic target (ESAT-6) antigen were compared to responses obtained using cells cultured with ESAT-6 for 6 days, using an ELISpot assay. RESULTS: In the ex vivo ELISpot assay, the median IFN-gamma responses in TB patients, irrespective of treatment status, were significantly higher than in healthy BCG-vaccinated controls. In the 6-day ELISpot assay, median IFN-gamma responses were significantly higher in TB patients who had completed treatment than in patients early during therapy. There was considerable individual variability in the degree of expansion of ESAT-6 specific T-cells from day 1 to day 6 in both treatment groups. CONCLUSION: Further studies are required to assess which type of assay provides the best indicator of a memory T-cell response and how ESAT-6 specific T-cells relate to protective immunity in TB infection.
OBJECTIVE: To investigate T-cell responses to ESAT-6 by an interferon-gamma (IFN-gamma) ex vivo enzyme-linked immunospot (ELISpot) assay in tuberculosis (TB) patients early during treatment and in patients who have completed a course of anti-tuberculosis chemotherapy. DESIGN: T-cell responses following overnight stimulation with 6-kD early secretory antigenic target (ESAT-6) antigen were compared to responses obtained using cells cultured with ESAT-6 for 6 days, using an ELISpot assay. RESULTS: In the ex vivo ELISpot assay, the median IFN-gamma responses in TB patients, irrespective of treatment status, were significantly higher than in healthy BCG-vaccinated controls. In the 6-day ELISpot assay, median IFN-gamma responses were significantly higher in TB patients who had completed treatment than in patients early during therapy. There was considerable individual variability in the degree of expansion of ESAT-6 specific T-cells from day 1 to day 6 in both treatment groups. CONCLUSION: Further studies are required to assess which type of assay provides the best indicator of a memory T-cell response and how ESAT-6 specific T-cells relate to protective immunity in TB infection.
Authors: S A Clark; S L Martin; A Pozniak; A Steel; B Ward; J Dunning; D C Henderson; M Nelson; B Gazzard; P Kelleher Journal: Clin Exp Immunol Date: 2007-08-02 Impact factor: 4.330
Authors: Annie F Luetkemeyer; Edwin D Charlebois; Laura L Flores; David R Bangsberg; Steven G Deeks; Jeffrey N Martin; Diane V Havlir Journal: Am J Respir Crit Care Med Date: 2007-01-11 Impact factor: 21.405
Authors: Tom G Connell; Mary-Ann Davies; Christine Johannisen; Kathryn Wood; Sandy Pienaar; Katalin A Wilkinson; Robert J Wilkinson; Heather J Zar; David Beatty; Mark P Nicol; Nigel Curtis; Brian Eley Journal: BMC Infect Dis Date: 2010-05-27 Impact factor: 3.090